# A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

> **NCT01677741** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 85 (actual)

## Conditions studied

- Neoplasms, Brain

## Interventions

- **DRUG:** Dabrafenib

## Key facts

- **NCT ID:** NCT01677741
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-23
- **Primary completion:** 2020-12-04
- **Final completion:** 2020-12-04
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01677741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01677741, "A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01677741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*